Gastroesophageal junction tumor
Conditions
Interventions
experimental group:PD-1 inhibitor + SOX chemotharapy + radiotherapy
Sponsors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Sign written informed consent prior to the implementation of any test-related procedures; 2. Male or female, aged 18 to 70 years; 3. Histologically confirmed gastroesophageal junction adenocarcinoma was diagnosed as CT3-4ANXM0 (AJCC 8th Edition) according to endoscopic ultrasonography, esophageal barium meal, or enhanced CT/MRI scan (CTNM). Siewert classification was II- normal type. 4. According to the efficacy evaluation criteria for solid tumors (RECIST 1.1), there should be at least one radiologically measurable lesion; 5. No previous surgical treatment or anti-tumor chemoradiotherapy/immunotherapy; 6. Patients who agree to undergo radical surgical treatment; 7. Patients with no obvious surgical contraindication judged by the surgeon to be able to perform radical resection initially; 8. ECOG score 0-1; 9. Expected survival time > 6 months.
Exclusion criteria
Exclusion criteria: 1. Other malignant diseases other than gastric cancer diagnosed within 5 years prior to the first administration (excluding radical basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and/or carcinoma in situ after radical resection); 2. Patients with preoperative endoscopic biopsy showing positive HER-2 (immunohistochemical +++, or positive FISH test); 3. Active bleeding signs of the lesion are known under endoscopy; 4. Is currently participating in an interventional clinical study treatment, or has received other investigational drugs or used investigational devices within 4 weeks prior to the first administration; 5. Have received the following therapies: anti-PD-1, anti-PD-L1 or anti-PD-L2; 6. Receive Chinese patent drugs with anti-tumor indications or drugs with immunomodulatory effect within 2 weeks before the first administration.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pathologic complete response; | — |
Countries
China
Contacts
Public ContactLiu hongli
Cancer Center of Union Medical College Affiliated Hospital of Tongji Medical College, Huazhong University of Science and Technology
Outcome results
None listed